Search results for "Deme"

showing 10 items of 883 documents

New Symptomatic Treatments for the Management of Motor and Nonmotor Symptoms of Parkinson's Disease

2017

Motor symptoms are core features of Parkinson's disease, while nonmotor symptoms are present from the prodromal stage. Management strategies for the motor symptoms of Parkinson's disease have been widely researched and there have been many advances. Therapy has evolved from oral therapy to once a day to nonoral strategies, both for rescue and for infusion therapy. Treatment for nonmotor symptoms, however, has remained a key unmet need, although of late evidence base for management of some nonmotor symptoms such as pain, dementia, aspects of sleep dysfunction, and constipation has emerged. However, management of many nonmotor symptoms such as anxiety, apathy, fatigue, and insomnia remains un…

0301 basic medicinemedicine.medical_specialtyConstipationParkinson's diseaseProdromal StageDiseasemedicine.diseasebody regions03 medical and health sciences030104 developmental biology0302 clinical medicinePhysical medicine and rehabilitationInfusion therapymedicineDementiaAnxietyApathymedicine.symptomPsychology030217 neurology & neurosurgery
researchProduct

Neurotrophic and neuroprotective effects of muscle contraction

2016

Background: Physical activity has been shown to be associated with reduced risk of coronary heart disease but the same effect seems to be produced in neurological diseases. Objective: In this review, we focused on the interplay between physical activity and some neurological conditions (Stroke, dementia, epilepsy, headache, Parkinson’ s disease, amyotrophic lateral sclerosis, multiple sclerosis, insomnia, depression and anxiety) with the aim of describing the potential role of physical activity in the prevention of such diseases and the physiological mechanisms involved in these processes. Results: Despite a growing body of evidence which reveals that physical activity is able to reduce the…

0301 basic medicinemedicine.medical_specialtyDiseaseBioinformaticsNeuroprotection03 medical and health sciencesEpilepsyPhysical medicine and rehabilitationDrug DiscoverymedicineHumansDementiaNervous System Physiological PhenomenaAmyotrophic lateral sclerosisStrokeExerciseLife StyleNervous System DiseaseDepression (differential diagnoses)EndocannabinoidPharmacologybusiness.industryPhysical activityMultiple sclerosisPreventionBrain-Derived Neurotrophic FactorRehabilitationOxidative Stremedicine.diseaseLifestyleStrokeOxidative Stress030104 developmental biologyCerebrovascular CirculationDementiaNervous System DiseasesbusinessNeurological diseaseEndocannabinoidsHumanMuscle Contraction
researchProduct

Vascular risk factors, white matter lesions and cognitive impairment in Parkinson’s disease: the PACOS longitudinal study

2020

Abstract Background Vascular risk factors (VRFs) may be associated with cognitive decline in early Parkinson’s disease (PD) but results are inconclusive. The identification of modifiable risk factors is relevant for prevention and treatment. Methods Parkinson’s disease (PD) patients of the PACOS cohort who underwent a baseline and follow-up neuropsychological evaluation were enrolled in the study. PD with Mild Cognitive Impairment (MCI) and dementia (PDD) were diagnosed according to the MDS criteria. A Baseline 1.5 T brain MRI was used to calculate the white matter lesions (WMLs) burden using the Wahlund visual scale. Laboratory data, presence of hypertension, diabetes and use of anti-hyper…

0301 basic medicinemedicine.medical_specialtyEpidemiologyNeuropsychological Testsbehavioral disciplines and activitiesWhite matter lesions03 medical and health sciences0302 clinical medicineInternal medicinemental disordersEpidemiologyHumansMedicineDementiaCognitive DysfunctionLongitudinal StudiesRisk factorCognitive declineOriginal CommunicationFramingham Risk Scorebusiness.industryMild cognitive impairmentParkinson DiseaseEpidemiology Hypertension Mild cognitive impairment Parkinson’s disease Risk factors White matter lesions Humans Longitudinal Studies Neuropsychological Tests Risk Factors Cognitive Dysfunction Parkinson Disease White Mattermedicine.diseaseWhite MatterHyperintensitynervous system diseases030104 developmental biologyBlood pressureRisk factorsNeurologyHypertensionCohortParkinson’s diseaseNeurology (clinical)business030217 neurology & neurosurgeryJournal of Neurology
researchProduct

Obesity as a Risk Factor for Alzheimer’s Disease: Implication of Leptin and Glutamate

2019

Obesity is known to induce leptin and insulin resistance. Leptin is a peptide hormone synthesized in adipose tissue that mainly regulates food intake. It has been shown that insulin stimulates the production of leptin when adipocytes are exposed to glucose to encourage satiety; while leptin, via a negative feedback, decreases the insulin release and enhances tissue sensitivity to it, leading to glucose uptake for energy utilization or storage. Therefore, resistance to insulin is closely related to leptin resistance. Obesity in middle age has also been related to Alzheimer’s disease (AD). In recent years, the relation between impaired leptin signaling pathway and the onset of AD has been stu…

0301 basic medicinemedicine.medical_specialtyMini Reviewmedicine.medical_treatmentGlucose uptakeExcitotoxicityAdipose tissuemedicine.disease_causelcsh:RC321-57103 medical and health sciences0302 clinical medicineInsulin resistanceInternal medicinemedicineoverweightleptin-resistanceReceptorlcsh:Neurosciences. Biological psychiatry. Neuropsychiatrybusiness.industryGeneral NeuroscienceInsulinLeptindigestive oral and skin physiologyGlutamate receptormedicine.disease030104 developmental biologyEndocrinologyLTPbusinessexcitotoxicity030217 neurology & neurosurgeryhormones hormone substitutes and hormone antagonistsNeurosciencedementiaFrontiers in Neuroscience
researchProduct

When Does Alzheimer′s Disease Really Start? The Role of Biomarkers

2021

While Alzheimer’s disease (AD) classical diagnostic criteria rely on clinical data from a stablished symptomatic disease, newer criteria aim to identify the disease in its earlier stages. For that, they incorporated the use of AD’s specific biomarkers to reach a diagnosis, including the identification of Aβ and tau depositions, glucose hypometabolism, and cerebral atrophy. These biomarkers created a new concept of the disease, in which AD’s main pathological processes have already taken place decades before we can clinically diagnose the first symptoms. Therefore, AD is now considered a dynamic disease with a gradual progression, and dementia is its final stage. With …

0301 basic medicinemedicine.medical_specialtyad spectrumGradual progressionVariable timeInfluential PublicationsReviewDiseaseCatalysislcsh:ChemistryInorganic Chemistry03 medical and health sciences0302 clinical medicineAlzheimer DiseaseRisk FactorsmedicineHumansDementiaPhysical and Theoretical ChemistryIntensive care medicineCognitive impairmentlcsh:QH301-705.5Molecular BiologyPathologicalad dynamicimaging biomarkersSpectroscopyCerebral atrophybusiness.industryOrganic ChemistrybiomarkerscsfGeneral Medicinemedicine.diseaseComputer Science Applications030104 developmental biologylcsh:Biology (General)lcsh:QD1-999business030217 neurology & neurosurgerydementiaInternational Journal of Molecular Sciences
researchProduct

2019

Aging causes many changes in the human body, and is a high risk for various diseases. Dementia, a common age-related disease, is a clinical disorder triggered by neurodegeneration. Brain damage caused by neuronal death leads to cognitive decline, memory loss, learning inabilities and mood changes. Numerous disease conditions may cause dementia; however, the most common one is Alzheimer’s disease (AD), a futile and yet untreatable illness. Adult neurogenesis carries the potential of brain self-repair by an endogenous formation of newly-born neurons in the adult brain; however it also declines with age. Strategies to improve the symptoms of aging and age-related diseases have included differe…

0301 basic medicinemedicine.medical_treatmentDiseaseBrain damageCatalysisInorganic Chemistry03 medical and health sciences0302 clinical medicineMedicineDementiaPhysical and Theoretical ChemistryCognitive declineMolecular BiologySpectroscopybusiness.industryOrganic ChemistryNeurodegenerationNeurogenesisGeneral MedicineStem-cell therapymedicine.diseaseComputer Science Applications030104 developmental biologymedicine.symptomStem cellbusinessNeuroscience030217 neurology & neurosurgeryInternational Journal of Molecular Sciences
researchProduct

Modulating disease-relevant tau oligomeric strains by small molecules

2020

The pathological aggregation of tau plays an important role in Alzheimer's disease and many other related neurodegenerative diseases, collectively referred to as tauopathies. Recent evidence has demonstrated that tau oligomers, small and soluble prefibrillar aggregates, are highly toxic due to their strong ability to seed tau misfolding and propagate the pathology seen across different neurodegenerative diseases. We previously showed that novel curcumin derivatives affect preformed tau oligomer aggregation pathways by promoting the formation of more aggregated and nontoxic tau aggregates. To further investigate their therapeutic potential, we have extended our studies o disease-relevant bra…

0301 basic medicinetau oligomeric strainsCurcuminTau proteinsmall moleculetau ProteinsProtein aggregationBiochemistrytau proteinoligomerProgressive supranuclear palsyprotein aggregationDiagnosis DifferentialSmall Molecule Libraries03 medical and health scienceschemistry.chemical_compoundBiopolymersmental disordersmedicineHumansMolecular BiologyCells CulturedNeurons030102 biochemistry & molecular biologybiologyChemistryDementia with Lewy bodiesbrain-derived tau oligomerstau aggregationtauopathytoxicityBrainMolecular Bases of DiseaseCell Biologymedicine.diseaseSmall moleculeImaging agentCell biology030104 developmental biologyTauopathiesbiology.proteinCurcuminTauopathyThe Journal of Biological Chemistry
researchProduct

Standardized on-road tests assessing fitness-to-drive in people with cognitive impairments: A systematic review.

2020

Objective The on-road assessment is the gold standard because of its ecological validity. Yet existing instruments are heterogeneous and little is known about their psychometric properties. This study identified existing on-road assessment instruments and extracted data on psychometric properties and usability in clinical settings. Method A systematic review identified studies evaluating standardized on-road evaluation instruments adapted for people with cognitive impairment. Published articles were searched on PubMed, CINHAL, PsycINFO, Web of Science, and ScienceDirect. Study quality and the level of evidence were assessed using the COSMIN checklist. The collected data were synthetized usi…

030506 rehabilitationResearch ValidityPsychometricsEcological validityApplied psychologySocial SciencesTransportationPsycINFO0302 clinical medicineCognitionMedicine and Health SciencesPsychologyCognitive ImpairmentMultidisciplinaryCognitive NeurologyQRResearch AssessmentTransportation InfrastructureTest (assessment)ProfessionsSystematic reviewNeurologyAutomobile Driver ExaminationEngineering and TechnologyMedicine0305 other medical sciencePsychologyResearch ArticleAutomobile DrivingPsychometricsSystematic ReviewsCognitive NeuroscienceScienceResearch and Analysis MethodsCivil Engineering03 medical and health sciencesMental Health and PsychiatryCriterion validityHumansCognitive Dysfunctionbusiness.industryBiology and Life SciencesUsabilityEvidence-based medicineAutomobile Driver Examination; Automobile Driving; Cognitive Dysfunction; Humans; Psychometrics/methodsRoadsInstructorsPeople and PlacesCognitive ScienceDementiaPopulation Groupingsbusiness030217 neurology & neurosurgeryNeurosciencePLoS ONE
researchProduct

Les taux de rendement privés et sociaux de l'éducation en France en 1970

1974

référence interne : 74003

1970Rendement privéTaux de rendement[SHS.EDU]Humanities and Social Sciences/Education[SHS.EDU] Humanities and Social Sciences/EducationRendement socialFranceRendement de l'éducation
researchProduct

Frequency and caregiver’s burden of frontotemporal dementia in ALS patients and their caregivers

ALS Frontotemporal dementia burden of careALS Frntotemporal dementia burden of care
researchProduct